Indoleamines and the central nervous system; a sounding of their clinical significance.
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001519:Behavior; D001833:Body Temperature Regulation; D001921:Brain / Q000378:metabolism; D002490:Central Nervous System; D003863:Depression / Q000378:metabolism; D004314:Down Syndrome / Q000378:metabolism; D006213:Hallucinogens / Q000378:metabolism; D006250:Hartnup Disease / Q000378:metabolism; D006801:Humans; D007211:Indoles; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008550:Melatonin / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology; D008881:Migraine Disorders / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism; D010649:Phenylalanine / Q000494:pharmacology; D010661:Phenylketonurias / Q000378:metabolism; D010870:Pineal Gland / Q000378:metabolism; D012559:Schizophrenia / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism / Q000502:physiology; D012702:Serotonin Antagonists; D012890:Sleep; D009435:Synaptic Transmission
D006213:Hallucinogens; D007211:Indoles; D012702:Serotonin Antagonists; D012701:Serotonin; D010649:Phenylalanine; D008238:Lysergic Acid Diethylamide; D000661:Amphetamine; D008550:Melatonin